Q2 2024 Earnings Estimate for bluebird bio, Inc. (NASDAQ:BLUE) Issued By William Blair

bluebird bio, Inc. (NASDAQ:BLUE) – Equities researchers at William Blair raised their Q2 2024 EPS estimates for bluebird bio in a research note issued on Tuesday, September 24th. William Blair analyst S. Corwin now forecasts that the biotechnology company will post earnings of ($0.41) per share for the quarter, up from their prior estimate of ($0.63). The consensus estimate for bluebird bio’s current full-year earnings is ($1.57) per share. William Blair also issued estimates for bluebird bio’s Q3 2024 earnings at ($0.39) EPS, Q4 2024 earnings at ($0.43) EPS, FY2024 earnings at ($1.58) EPS, Q1 2025 earnings at ($0.25) EPS, Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at $0.01 EPS, Q4 2025 earnings at ($0.51) EPS and FY2025 earnings at ($0.80) EPS.

A number of other research firms also recently weighed in on BLUE. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $4.00 price target on shares of bluebird bio in a research note on Thursday, August 15th. Barclays cut their price objective on shares of bluebird bio from $8.00 to $4.00 and set an “overweight” rating for the company in a report on Thursday, August 15th. Bank of America decreased their target price on shares of bluebird bio from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Thursday, August 15th. JPMorgan Chase & Co. downgraded bluebird bio from an “overweight” rating to a “neutral” rating in a research report on Thursday, August 15th. Finally, Wells Fargo & Company lowered their price objective on shares of bluebird bio from $3.00 to $2.00 and set an “equal weight” rating for the company in a report on Wednesday. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $4.63.

bluebird bio Stock Performance

Shares of bluebird bio stock opened at $0.50 on Friday. bluebird bio has a 1-year low of $0.46 and a 1-year high of $5.53. The company has a current ratio of 0.93, a quick ratio of 0.82 and a debt-to-equity ratio of 0.20. The business has a 50-day moving average price of $0.77 and a two-hundred day moving average price of $0.97. The company has a market cap of $55.15 million, a P/E ratio of -0.68 and a beta of 0.75.

Institutional Trading of bluebird bio

Several institutional investors and hedge funds have recently bought and sold shares of the business. Allegheny Financial Group LTD purchased a new position in bluebird bio in the 2nd quarter valued at about $25,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of bluebird bio during the fourth quarter worth approximately $37,000. Enterprise Bank & Trust Co purchased a new stake in shares of bluebird bio during the first quarter worth approximately $38,000. China Universal Asset Management Co. Ltd. raised its stake in bluebird bio by 189.2% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 36,580 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 23,933 shares during the last quarter. Finally, Sequoia Financial Advisors LLC lifted its holdings in bluebird bio by 48.0% in the 1st quarter. Sequoia Financial Advisors LLC now owns 40,085 shares of the biotechnology company’s stock valued at $51,000 after purchasing an additional 13,000 shares in the last quarter. 87.43% of the stock is currently owned by institutional investors and hedge funds.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.